<DOC>
	<DOCNO>NCT02925117</DOCNO>
	<brief_summary>This 40-week Phase 2b , randomize , double-blind , parallel-group , placebo-controlled multicenter study evaluate safety efficacy ABT-494 adult participant moderate severe atopic dermatitis . The participant randomize 1:1:1:1 ratio one four treatment group .</brief_summary>
	<brief_title>A Study Evaluate ABT-494 Adult Subjects With Moderate Severe Atopic Dermatitis</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<criteria>Atopic dermatitis diagnosis confirm dermatologist ( accord Hanifin Rajka criterion ) onset symptom least 1 year prior baseline . Moderate severe atopic dermatitis define Eczema Area Severity Index ( EASI ) &gt; = 16 , Body Surface Area ( BSA ) &gt; = 10 % Investigators Global Assessment ( IGA ) score &gt; = 3 Baseline visit . Documented history ( within 1 year prior screen visit ) inadequate response treatment topical corticosteroid ( TCS ) , topical calcineurin inhibitor ( TCI ) , topical treatment otherwise medically inadvisable ( e.g. , important side effect safety risk ) . Twice daily use additivefree , bland emollient least 7 day prior Baseline . Prior exposure systemic topical JAK inhibitor ( include limit tofacitinib , baricitinib , ruxolitinib , filgotinib ) . Treatment topical corticosteroid ( TCS ) , topical calcineurin inhibitor ( TCI ) , prescription moisturizers moisturizers contain additive ceramide , hyaluronic acid , urea , filaggrin within 10 day prior Baseline visit . Prior exposure dupilumab . Prior exposure investigational systemic treatment within 30 day 5 halflives ( whichever longer ) Baseline visit currently enrol another clinical study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>ABT-494</keyword>
	<keyword>Atopic Dermatitis</keyword>
</DOC>